

GlaxoSmithKline

To: Tamala Holland

From: Jason C. Fedon

Faxe

571-273-9786

Pages: 4 (including cover page)

Phone: 703-308-9140 ex 209

Date:

13 January 2006

Attorney Docket No.: PG4939A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ashman, et al.

13 January 2005

US Appln. No.:

10/526,151

Group Art Unit No.: Unknown

Filed:

28 February 2005

Examiner:

Unknown

For:

VACCINE COMPRISING IL-13 AND AN ADJUVANT

RESPONSE TO NOTICE TO COMPLY

Sirs:

This paper is in response to the Notification to Comply with Requirements for Patent Applications containing nucleotide and/or amino acid sequence disclosures. Further to the conversation between Tamala Holland and Christina Doyle, enclosed is a copy of the returned post card as well as a copy of the previously submitted Statement to Support Filing. If it would expedite prosecution of this application, the Examiner is invited to confer with the Applicants' undersigned attorney.

Respectfully submitted,


Jason C. Fedon Agent for Applicants Registration No. 48,138

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-6150 Facsimile (610) 270-5090

apport Filing co to Camply aper Seq. List pages st tage (2nd sub) tten Opinion ment neal/Brief Req pgs. ct Filing Recept agg Receipt section (2)pgs. x2
ecticm (2)pgs.x2

the first process armen's recommendate or the real columns of the	· · · · · · · · · · · · · · · · · · ·
DOCKET No. 1649394 Date Mailed 26 MAILING: CERTIFICATE EXPRESS MAIL # EU.S. Scrial No. 1: 100 KNOR 100 Filing Int'l App. No.: 2016803/03791 Int'l 1	v 453422505 US
RECEIPT IS ACKNOWLEDGED FOR THE FOLLO Appln. Trans. for:	Statement to Support Filing Copy of Notice to Comply Soliskette ■ Paper Seq.List Appeal Brief pages Petition pgs.





"EXPRESS MAIL CERTIFICATE" "EXPRESS MAIL" MAILING LABEL NUMBER EV453422505US DATE OF DEPOSIT 28 February 2005

Attorney Docket No.: PG4939A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ashman et al.

28 February 2005

Int'l. Appln. No.: PCT/GB03/03721

Group Art Unit No.: Unknown

Filed:

28 August 2003

Examiner:

Unknown


For:

VACCINE COMPRISING IL-13 AND AN ADJUVANT

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

Commissioner for Patents
Mail Stop: Sequence
P.O. Box 1450
Alexandria, Va 22313-1450

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.
- (X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (g) does not include new matter.
- (X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 CFR §1.825
 (a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.



() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,

Sason C. Fedon
Agent for Applicants
Registration No. 48,138

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090
pg4938\Sequence Listing Transmittal.doc